| Enblo (enavogliflozin) / Daewoong Pharma, GC Biopharma, M8 Pharma |
ENHANCE-M, NCT04634500: The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes. |
|
|
| Completed | 3 | 200 | RoW | Dapagliflozin, DWP16001 | Daewoong Pharmaceutical Co. LTD. | T2DM (Type 2 Diabetes Mellitus) | 11/21 | 11/21 | | |
NCT04632862: The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus. |
|
|
| Completed | 3 | 140 | RoW | DWP16001 | Daewoong Pharmaceutical Co. LTD. | T2DM (Type 2 Diabetes Mellitus) | 11/21 | 11/21 | | |
NCT04654390: The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus |
|
|
| Completed | 3 | 270 | RoW | DWP16001 Amg | Daewoong Pharmaceutical Co. LTD. | T2DM (Type 2 Diabetes Mellitus) | 12/21 | 12/21 | | |
ENHANCE-MEXT, NCT05376969: Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin |
|
|
| Completed | 3 | 159 | RoW | DWP16001 | Daewoong Pharmaceutical Co. LTD. | T2DM (Type 2 Diabetes Mellitus) | 05/22 | 05/22 | | |
NCT05376930: Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM. |
|
|
| Completed | 3 | 63 | RoW | DWP16001 Amg | Daewoong Pharmaceutical Co. LTD. | T2DM (Type 2 Diabetes Mellitus) | 05/22 | 05/22 | | |
NCT06141980: Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 3 | 134 | NA | DWP16001 0.3 mg | Daewoong Pharmaceutical Co. LTD. | T2DM (Type 2 Diabetes Mellitus) | 09/25 | 09/25 | | |
NCT05505994: The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin |
|
|
| Active, not recruiting | 3 | 340 | RoW | DWP16001, DWP16001 tablet, Dapagliflozin, Dapagliflozin tablet, DWP16001 Placebo, DWP16001 Placebo tablet, Dapagliflozin Placebo, Dapagliflozin Placebo tablet | Daewoong Pharmaceutical Co. LTD. | Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases | 02/24 | 09/24 | | |
ENHANCE-I, NCT05466643: A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus |
|
|
| Recruiting | 3 | 240 | RoW | DWP16001 0.3mg, DWP16001 Placebo | Daewoong Pharmaceutical Co. LTD. | Type 2 Diabetes Mellitus | 09/24 | 09/24 | | |
| Recruiting | 3 | 540 | RoW | Enavogliflozin, Envlo (brand name), Placebo | Asan Medical Center, Daewoong Pharmaceutical Co. LTD. | Tricuspid Regurgitation, Heart Failure With Preserved Ejection Fraction | 04/26 | 10/27 | | |
